Annovis Bio Future Growth
Future criteria checks 0/6
Annovis Bio's earnings are forecast to decline at 20.4% per annum while its annual revenue is expected to grow at 74% per year. EPS is expected to grow by 11.2% per annum. Return on equity is forecast to be -46.5% in 3 years.
Key information
-20.4%
Earnings growth rate
11.2%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 74.0% |
| Future return on equity | -46.5% |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -52 | -46 | -45 | 4 |
| 12/31/2025 | N/A | -37 | -35 | -35 | 5 |
| 12/31/2024 | N/A | -24 | -21 | -21 | 5 |
| 9/30/2024 | N/A | -41 | -23 | -23 | N/A |
| 6/30/2024 | N/A | -43 | -29 | -29 | N/A |
| 3/31/2024 | N/A | -48 | -35 | -35 | N/A |
| 12/31/2023 | N/A | -56 | -40 | -40 | N/A |
| 9/30/2023 | N/A | -42 | -34 | -34 | N/A |
| 6/30/2023 | N/A | -33 | -29 | -29 | N/A |
| 3/31/2023 | N/A | -30 | -26 | -26 | N/A |
| 12/31/2022 | N/A | -25 | -17 | -17 | N/A |
| 9/30/2022 | N/A | -24 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -20 | -13 | -13 | N/A |
| 3/31/2022 | N/A | -17 | -10 | -10 | N/A |
| 12/31/2021 | N/A | -14 | -9 | -9 | N/A |
| 9/30/2021 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2021 | N/A | -8 | -7 | -7 | N/A |
| 3/31/2021 | N/A | -8 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -5 | -4 | -4 | N/A |
| 9/30/2020 | N/A | -4 | -3 | -3 | N/A |
| 6/30/2020 | N/A | -3 | -2 | -2 | N/A |
| 3/31/2020 | N/A | -1 | -1 | -1 | N/A |
| 12/31/2019 | N/A | -1 | 0 | 0 | N/A |
| 9/30/2019 | N/A | -1 | -1 | -1 | N/A |
| 6/30/2019 | N/A | -1 | -1 | -1 | N/A |
| 3/31/2019 | N/A | -1 | -1 | -1 | N/A |
| 12/31/2018 | N/A | -1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 07X is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 07X is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 07X is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 07X is forecast to have no revenue next year.
High Growth Revenue: 07X is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 07X is forecast to be unprofitable in 3 years.